Aprea Therapeutics, Inc.
APRE- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001781983
No open-market purchases or sales by Aprea Therapeutics, Inc. insiders were filed in the last 90 days; 27 institutions reported holding it in 13F filings for Q2 2026, worth $1.90M in total; no superinvestor holds it.
Q2 2025 vs. Q1 2025
How the institutions holding Aprea Therapeutics, Inc. changed between Q1 2025 and Q2 2025.
All holders in Q2 2025All holders in Q1 2025
| Measure | Q1 2025 | Q2 2025 | Change |
|---|---|---|---|
| Holders | 26 | 23 | −3 |
| Shares | 1.95M | 1.82M | −134.2K (−6.9%) |
| Value | $3.78M | $3.07M | −$711.0K (−18.8%) |
New holders (1)
Institutions that held Aprea Therapeutics, Inc. at the end of Q2 2025 but not at the end of Q1 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| FMR LLC | 501 | $852 | 0.00% |
Sold out (4)
Institutions that held Aprea Therapeutics, Inc. at the end of Q1 2025 and filed for Q2 2025 without it.
| Institution | Shares, Q1 2025 | Value, Q1 2025 |
|---|---|---|
| Citadel Advisors LLC | 30,083 | $61.4K |
| Exome Asset Management LLC | 28,972 | $59.1K |
| Stonepine Capital Management, LLC | 102,242 | $14.4K |
| JPMorgan Chase & Co | 10 | $20 |